Literature DB >> 25109884

Pathological features of fatty liver disease.

Matthew M Yeh1, Elizabeth M Brunt2.   

Abstract

Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are significant causes of chronic liver disease worldwide. Both are characterized by histological lesions that can include steatosis, and each can lead to cirrhosis. It might be possible for pathologists to identify lesions and patterns of ALD and NAFLD; we review these lesions and propose methods to distinguish between the disorders. Any form of ALD can lead to end-stage liver disease, according to long-term studies of biopsy specimens and patient outcomes. Although steatosis can be a significant cofactor in progression of established chronic liver disease, or even development of hepatocellular carcinoma, only steatohepatitis indicates the presence of progressive liver disease in patients with NAFLD. Pediatric and adolescent NAFLD differ from adult nonalcoholic steatohepatitis and should be recognized as distinct conditions. Benign and malignant liver tumors have been more frequently reported with the increasing prevalence of obesity and diabetes. Histological scoring systems for ALD and NAFLD have been proposed to monitor efficacy in clinical trials and serve as prognostic factors. We review what we have learned from pathological analyses about the development of these disorders and how this information might be used to detect and treat them.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Histology; NASH; Prognosis

Mesh:

Year:  2014        PMID: 25109884     DOI: 10.1053/j.gastro.2014.07.056

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  106 in total

1.  Function of inhibitor of Bruton's tyrosine kinase isoform α (IBTKα) in nonalcoholic steatohepatitis links autophagy and the unfolded protein response.

Authors:  Jeffrey A Willy; Sara K Young; Amber L Mosley; Samer Gawrieh; James L Stevens; Howard C Masuoka; Ronald C Wek
Journal:  J Biol Chem       Date:  2017-07-14       Impact factor: 5.157

2.  Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model.

Authors:  Reilly T Enos; Kandy T Velázquez; Jamie L McClellan; Taryn L Cranford; Michael D Walla; E Angela Murphy
Journal:  Nutr Res       Date:  2015-04-11       Impact factor: 3.315

3.  A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease.

Authors:  Steven E Trasino; Xiao-Han Tang; Jose Jessurun; Lorraine J Gudas
Journal:  J Mol Med (Berl)       Date:  2016-06-06       Impact factor: 4.599

4.  Gaps in Knowledge and Research Priorities for Alcoholic Hepatitis.

Authors:  Arun J Sanyal; Bin Gao; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2015-05-23       Impact factor: 22.682

5.  Tubulin alpha 8 is expressed in hepatic stellate cells and is induced in transformed hepatocytes.

Authors:  Lisa Rein-Fischboeck; Rebekka Pohl; Elisabeth M Haberl; Sebastian Zimny; Maximilian Neumann; Kristina Eisinger; Thomas S Weiss; Sabrina Krautbauer; Christa Buechler
Journal:  Mol Cell Biochem       Date:  2017-01-07       Impact factor: 3.396

6.  Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress.

Authors:  Tianhui Liu; Ping Wang; Min Cong; Xinyan Zhao; Dong Zhang; Hufeng Xu; Lin Liu; Jidong Jia; Hong You
Journal:  Br J Pharmacol       Date:  2018-10-23       Impact factor: 8.739

7.  Altered expression of hepatic β-adrenergic receptors in aging rats: implications for age-related metabolic dysfunction in liver.

Authors:  Yun Shi; Zhen-Ju Shu; Hanzhou Wang; Jeffrey L Barnes; Chih-Ko Yeh; Paramita M Ghosh; Michael S Katz; Amrita Kamat
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-12-06       Impact factor: 3.619

Review 8.  [The intestinal microbiome and metabolic diseases : From obesity to diabetes and nonalcoholic steatohepatitis].

Authors:  S C Bischoff
Journal:  Internist (Berl)       Date:  2017-05       Impact factor: 0.743

9.  E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis.

Authors:  Pierre-Damien Denechaud; Isabel C Lopez-Mejia; Albert Giralt; Qiuwen Lai; Emilie Blanchet; Brigitte Delacuisine; Brandon N Nicolay; Nicholas J Dyson; Caroline Bonner; François Pattou; Jean-Sébastien Annicotte; Lluis Fajas
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

Review 10.  Caring for children with NAFLD and navigating their care into adulthood.

Authors:  Ali A Mencin; Rohit Loomba; Joel E Lavine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-01       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.